UBS Group’s Novo Nordisk NVO Stock Holding History

UBS Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103M	Sell	2,148,100 -695,000	-24%	-$29.9M	0.01%	1099
2026 Q1	$104M	Buy	2,843,100 +1,075,700	+61%	+$51M	0.02%	1020
2025 Q4	$89.9M	Sell	1,767,400 -50,000	-3%	-$2.56M	0.01%	1093
2025 Q3	$101M	Buy	1,817,400 +1,756,700	+2,894%	+$103M	0.02%	1025
2025 Q2	$4.19M	Sell	60,700 -585,200	-91%	-$39.8M	﹤0.01%	4056
2025 Q1	$44.9M	Buy	645,900 +588,900	+1,033%	+$48.6M	0.01%	1577
2024 Q4	$4.9M	Buy	+57,000	New	+$6.16M	﹤0.01%	3874
2020 Q4	–	Sell	-600	Closed	-$21K	–	8628
2020 Q3	$21K	Buy	+600	New	+$20K	﹤0.01%	6278
2020 Q2	–	Sell	-200	Closed	-$6K	–	8232
2020 Q1	$6K	Buy	+200	New	+$5.96K	﹤0.01%	7226
2015 Q3	–	Sell	-80,000	Closed	-$2.19M	–	8557
2015 Q2	$2.19M	Buy	+80,000	New	+$2.25M	﹤0.01%	2886

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group's NVO Position: Q2 2026 in Review

UBS Group reduced its Novo Nordisk (NVO) stake by 13% in Q2 2026, selling an estimated $25M and leaving 3,984,940 shares worth $191M. The position accounts for 0.02% of the portfolio, ranked #694.

UBS Group first reported a position in NVO in Q4 2014 and has held it in 47 quarters since. The position peaked at $250M in Q4 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

UBS Group held 3,984,940 shares of Novo Nordisk worth $191M as of Q2 2026.
UBS Group sold 580,768 Novo Nordisk shares in Q2 2026, an estimated $25M.
Novo Nordisk made up 0.02% of UBS Group's portfolio in Q2 2026, its #694 holding.
UBS Group first reported a position in Novo Nordisk in Q4 2014 and has held it in 47 quarters since.
UBS Group's Novo Nordisk position peaked at $250M in Q4 2025.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.